Observational study of safety and effectiveness of NovoMix 30 (biphasic insulin aspart) for the treatment of diabetes mellitus.

Trial Profile

Observational study of safety and effectiveness of NovoMix 30 (biphasic insulin aspart) for the treatment of diabetes mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Insulin aspart/insulin protamine aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms IMPROVE
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 15 Jun 2012 Actual initiation date changed from 1 Feb 2006 to 1 Sep 2006 as reported by ClinicalTrials.gov.
    • 14 Jan 2009 Actual patient number reported as 58223 by ClinicalTrials.gov.
    • 14 Jan 2009 Actual end date reported as November 2008 by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top